AIM ImmunoTech enters ATM offering agreement for up to $3M common stock

AIM ImmunoTech Inc.

Entered Equity Distribution Agreement with Maxim Group LLC for at-the-market offering of up to $3M common stock.
Currently limited to selling $663,329 due to Form S-3 General Instruction I.B.6; registration statement not yet effective.
Maxim receives 3.0% commission on gross proceeds; expense reimbursement up to $50,000 initial, $5,000 quarterly.
Net proceeds to be used for working capital and general corporate purposes.
Agreement may be terminated by either party on 15 days' notice or after 24 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.